Jean-Loup Romet-Lemonne
Director/Board Member at Antabio SAS
Network origin in Jean-Loup Romet-Lemonne first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA.
13
| Extinct | Pharmaceuticals: Major | 13 |
Antabio SAS
 Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Jean-Loup Romet-Lemonne via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO Director/Board Member | |
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Chief Operating Officer Director/Board Member Director/Board Member | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| MIRUM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Founder | |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Chairman Director/Board Member | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
Horizon Therapeutics USA, Inc.
 Horizon Therapeutics USA, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
Alta Partners Management Co. LP
 Alta Partners Management Co. LP Investment ManagersFinance Alta Partners Management Co. LP (Alta Partners) is a venture capital firm founded in 1996 by Jean Deleage, Guy Paul Nohra, Marino Polestra and Garrett P. Gruener. The firm is headquartered in Jackson, Wyoming. | Investment Managers | Private Equity Investor Founder | |
Plexium, Inc.
 Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chairman | |
| Northern Illinois University | College/University | Undergraduate Degree | |
Ziarco Pharma Ltd.
 Ziarco Pharma Ltd. BiotechnologyHealth Technology Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom. | Biotechnology | Chairman | |
| RENEO PHARMACEUTICALS, INC. | Biotechnology | Founder | |
Ziarco Group Ltd.
 Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Balance Therapeutics, Inc.
 Balance Therapeutics, Inc. BiotechnologyHealth Technology Balance Therapeutics, Inc. develops therapeutics to address conditions of intellectual disability. Its pharmacological approach, based on technology licensed from Stanford University, hypothesizes that restoring the proper balance between inhibition and excitation at the neuronal synapse by antagonizing excessive inhibitory circuits could result in the appropriate plasticity for memory and learning to occur in many conditions of intellectual disability. The company was founded by Lyndon Lien, Craig Garner and Daniel Wetmore in 2009 and is headquartered in San Bruno, CA. | Biotechnology | Director/Board Member | |
| MIRATI THERAPEUTICS | Biotechnology | Director/Board Member | |
| E I DU PONT DE NEMOURS AND CO | Chemicals: Agricultural | Chief Tech/Sci/R&D Officer | |
RiverVest Venture Management LLC
 RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri. | Investment Managers | Private Equity Investor | |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Executive Officer | |
Biothera, Inc.
 Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN. | Miscellaneous Commercial Services | Director/Board Member | |
Sorriso Pharmaceuticals, Inc.
 Sorriso Pharmaceuticals, Inc. BiotechnologyHealth Technology Sorriso Pharmaceuticals, Inc. is an American biotechnology company that focuses on developing disease-modifying antibodies to treat inflammatory diseases. Sorriso Pharmaceuticals was founded by Ciara Kennedy, who has been the CEO since its incorporation. | Biotechnology | Chairman | |
Curzion Pharmaceuticals, Inc.
 Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Executive Officer | |
| SPRUCE BIOSCIENCES, INC. | Biotechnology | Chairman | |
| The University of Chicago | College/University | Doctorate Degree | |
| Ansan, Inc. | Miscellaneous | President | |
Biothera Pharmaceutical, Inc.
 Biothera Pharmaceutical, Inc. Medical/Nursing ServicesHealth Services Biothera Pharmaceutical, Inc. operates as a biotechnology company. It develops Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation. The company was founded in 1997 and is headquartered in Roseville, MN. | Medical/Nursing Services | Director/Board Member | |
Pappas Capital LLC
 Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Investment Managers | Private Equity Investor | |
| University of California, Los Angeles | College/University | Undergraduate Degree | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Director/Board Member | |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Biotechnology | Chairman | |
Metriopharm AG
 Metriopharm AG Pharmaceuticals: MajorHealth Technology Metriopharm AG engages in the development and manufacture of pharmaceutical products. It offers pipeline, indicators and clinical trials. The company was founded by Ekkehard Brysch and Wolfgang Brysch in 2007 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Chairman | |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Medical Specialties | President | |
| GALENICA AG | Medical Distributors | Director/Board Member | |
EIP Pharma, Inc.
 EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
Novo Nordisk Ltd.
 Novo Nordisk Ltd. Medical/Nursing ServicesHealth Services Novo Nordisk Ltd. engages in the sale and marketing of pharmaceutical products for the treatment of chronic conditions in the United Kingdom. It offers medicines for the treatment of diabetes, and hemophilia and bleeding disorders, as well as for growth hormone therapy and hormone replacement therapy. The company is headquartered in Crawley, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
| Séminaire de Sherbrooke | College/University | Undergraduate Degree | |
Revvity BV
 Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | Medical Specialties | Director/Board Member | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| CERVOMED INC. | Miscellaneous Commercial Services | Director/Board Member | |
| AUSPEX PHARMACEUTICALS INC | Pharmaceuticals: Major | President |
Statistics
International
| United States | 37 |
| United Kingdom | 6 |
| Denmark | 3 |
| France | 3 |
| Switzerland | 3 |
Sectoral
| Health Technology | 33 |
| Consumer Services | 6 |
| Finance | 6 |
| Commercial Services | 4 |
| Health Services | 3 |
Operational
| Director/Board Member | 136 |
| Corporate Officer/Principal | 45 |
| Chairman | 35 |
| Independent Dir/Board Member | 29 |
| President | 27 |
Most connected contacts
| Insiders | |
|---|---|
| Timothy Walbert | 40 |
| Michael Grey | 32 |
| Edward Penhoet | 29 |
| John McKearn | 25 |
| Sylvie Grégoire | 25 |
| Jean Deleage | 23 |
| Donald Lee Drakeman | 13 |
| Robert J. de Vaere | 12 |
| Benedikt Timmerman | 11 |
| Emile Loria | 10 |
| Gordon Waldron | 8 |
| Robert Beck | 7 |
| Claire Poulard | 7 |
| James G. Bender | 5 |
| Helmuth van Es | 5 |
- Stock Market
- Insiders
- Jean-Loup Romet-Lemonne
- Company connections
